Tokyo – a group of Japanese researchers announced this Friday transplanted induced pluripotent stem cells (iPS) in the brain of a patient suffering from a disease Parkinson the first trial of this kind in the world.
The team from the University of Kyoto injected 2.4 million iPS cells – capable of generating any cell type – in the left part of the brain during a three-hour operation in October.
The man, about 50 years old, has been well treated and remains under the supervision of two years, said in a statement at the University of Kyoto.
If a problem occurs in the next six months, researchers will implant 2.4 million additional cells, this time in the right part of the brain.
These iPS cells from healthy donors should develop into neurons that produce dopamine, a neurotransmitter who intervenes in the control of motor skills.
The University of Kyoto announced in July that it will conduct a clinical trial with seven people between the ages of 50 and 69.
Parkinson's disease is characterized by neuronal degeneration, with progressively aggravated symptoms such as jitter, muscle stiffness, and loss of physical fitness.
It affects more than ten million people worldwide, according to the Foundation against Disease Parkinson USA, The currently available therapies "improve the symptoms without slowing the progression of the disease," explains the foundation.
New investigations aimed at turning the evil.
Prior to human clinical screening, experiments were carried out on monkeys with human stem cells that allowed the enhancement of primate initiation ability caused by a type of Parkinson's disease, according to a study published in late August 2017 in Science,
Two years survival of transplanted cells was monitored by injection into the brain of the primate and no tumor was detected.
Stimulated pluripotent stem cells (iPSs) are adult cells reduced to their almost embryonic state to generate four genes (normally inactive in adults). This genetic manipulation restores the ability to produce any cell to the site where they are transplanted.
The use of iPS cells does not represent significant ethical problems, unlike stem cells obtained from human embryos.